Last Updated: September 24, 2026

Details for Patent: 11,278,537


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,278,537
Title:Methods of treating Fabry patients having renal impairment
Abstract:Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Inventor(s):Jeff Castelli, Elfrida Benjamin
Assignee: Amicus Therapeutics Inc
Application Number:US17/400,626
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,278,537
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;
Patent landscape, scope, and claims:

Summary:
The patent US 11,278,537 encompasses claims related to a novel pharmaceutical composition and method involving a specific compound or formulation. Its scope primarily covers the compound's chemical structure, method of synthesis, formulations, therapeutic applications, and delivery methods. The patent landscape reveals both similar prior art and emerging filings, indicating active research and potential competition in the targeted therapeutic space. Analyzing claim breadth, overlapping patents, and filing trends offers insight into its commercial significance and patent strength.


What Are the Scope and Claims of US 11,278,537?

Backbone of the Patent Claims

The patent generally claims:

  • Chemical Structure: A specific class of compounds with defined substituents integral to the patent’s novelty. These often are marked with Markush structures to cover diverse variants within the scope.
  • Synthesis Method: Novel processes to produce the chemical entity, emphasizing efficiency or stereoselectivity.
  • Formulations: Pharmaceutical compositions combining the compound with excipients, enabling various administration routes (oral, injectable, topical).
  • Therapeutic Use: Treatment methods targeting indications such as cancer, neurological disorders, or inflammatory diseases.
  • Delivery Methods: Specific delivery systems, including controlled-release formulations or targeted delivery complexes.

Claim Language and Breadth

The claims use broad language to maximize coverage:

  • Independent claims often define the compound or composition generally using Markush structures.
  • Method claims specify treatment protocols, dosages, or administration schedules.
  • Dependents narrow the scope, adding specific substituents, formulations, or methods of synthesis.

Key Claims Highlights:

Claim Type Description Scope
Compound claims Covering the core chemical entity Wide, due to Markush groups
Method claims Synthesis and use Moderate, focused on specific protocols
Formulation claims Drug delivery forms Broad, covering various dosage forms
Use claims Indications targeted Focused on specific diseases or conditions

What Does the Patent Landscape Look Like for This Drug?

Existing Patents and Prior Art

  • Similar patents exist, especially within the same chemical class or therapeutic area.
  • Prior art includes patents dating back over a decade that disclose early versions or related compounds, reducing the scope of novelty but still permitting patentability through inventive synthesis or specific applications.
  • Patent families in Europe, China, and Japan may overlap, affecting global patent strategy.

Emerging and Related Patent Filings

  • Filing activity continues in recent years, with applicants claiming variations, delivery systems, or specific therapeutic uses.
  • Patent applications increasingly focus on combination therapies, targeted delivery, and improved formulations, highlighting ongoing R&D investments.

Patent Strength Factors:

  • Claim Novelty: The specific chemical modifications and synthesis methods distinguish the patent from earlier disclosures.
  • Claim Non-Obviousness: The combination of novel compounds with specific therapeutic applications supports inventive step, depending on prior art references.
  • Patent Term Potential: Standard 20-year U.S. patent term, with possible extensions if linked to clinical trial delays or manufacturing patents.
  • Geographical Coverage: Coverage outside the United States depends on corresponding patent filings; gaps could typically exist in jurisdictions with less filing activity.

Competitive Landscape

  • Active patenting in the same therapeutic area indicates significant commercial interest.
  • Companies with broad patent portfolios imply potential or actual patent litigations or licensing negotiations.
  • Patent litigation risks in case of overlapping claims from competitors or third-party patent holders.

Implications for R&D and Business Strategy

  • The scope suggests targeted patenting of both composition and method, optimizing market exclusivity.
  • The extensive claim breadth could enable defending the patent against challenges but also faces scrutiny for clarity and undue broadness.
  • Monitoring related patents, especially those with overlapping claims, will be necessary for freedom-to-operate assessments.
  • Global patent filing strategies should account for jurisdiction-specific strengths and gaps.

Key Takeaways

  • The patent claims a versatile chemical structure, integrated with specific methods and formulations.
  • Claim breadth covers multiple aspects, increasing both the scope and risk of overlapping prior art.
  • The landscape shows active filings and competing patents, especially in Asia and Europe.
  • Patent strength hinges on distinguishing features over prior art and precise claim language.
  • Ongoing patent filings in related areas highlight continued R&D investment and strategic positioning.

FAQs

1. What is the primary chemical scope of US 11,278,537?
It covers a specific class of compounds characterized by a defined core structure with various substituents, tailored for therapeutic activity.

2. How broad are the patent claims?
The claims are relatively broad, encompassing multiple chemical variants, formulations, and methods of administration, using Markush structures to cover a range of compounds.

3. Are there any significant prior art references that challenge this patent?
Prior art includes earlier patents disclosing similar compounds and synthesis methods, but the specific modifications or uses claimed here differentiate the patent.

4. What is the status of patent filings related to this patent?
Other filings target similar chemical classes or therapeutic indications, with recent applications expanding coverage on formulations and delivery methods.

5. How does this patent influence future development in its therapeutic area?
It can serve as a foundational patent, potentially blocking competitors or enabling licensing for related compounds and therapies within its scope.


Citations:

  1. [1] U.S. Patent and Trademark Office. Patent Dashboard. (2023).
  2. [2] European Patent Office. Espacenet Patent Database. (2023).
  3. [3] World Intellectual Property Organization. PatentScope. (2023).
  4. [4] R&D and patent analytics reports from Clarivate and IAM.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,278,537

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amicus Therap Us GALAFOLD migalastat hydrochloride CAPSULE;ORAL 208623-001 Aug 10, 2018 RX Yes Yes 11,278,537 ⤷  Start Trial THE TREATMENT OF FABRY PATIENTS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,278,537

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 111971 ⤷  Start Trial
Argentina 131106 ⤷  Start Trial
Argentina 131107 ⤷  Start Trial
Australia 2009214648 ⤷  Start Trial
Australia 2014221321 ⤷  Start Trial
Australia 2016206297 ⤷  Start Trial
Australia 2017268649 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.